A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

It's only the first day of summer and record high temperatures are already being reported across much of the U.S. with a ...

This valuable manuscript investigates the localisation of nutrient receptors in bloodstream stage trypanosomes, with implications for both nutrient uptake and immune evasion. Results after direct ...

Beta receptors (beta-1, beta-2 and beta-3) are more involved in heart rate, muscle relaxation and metabolic functions. Understanding alpha receptors vs. beta receptors is essential for ...

Long-Term Beta-Cell Restoration Potential: Insulin deficient patients who received icovamenib (n=45) demonstrated a persistent increase in C-peptide levels beyond the active treatment period, over 3 ...

We showed in the mouse experiments that beta-2 and beta-3 were the important beta-adrenergic receptors, not beta-1. Once we had that result, ...

According to Loomba, up to 75% of VK2809-treated patients achieved MASH resolution with no worsening of fibrosis vs. 29.3% of placebo-treated patients (P < .0001).